晚期卵巢癌女性接受新辅助化疗的相关因素
基于美国国家癌症数据库2012至2014年诊断为IIIC期和IV期上皮性卵巢癌的17302例女性,10948例(63.3%)接受初始肿瘤细胞减灭术,6354例(36.7%)接受新辅助化疗。高龄、IV期、高级别和浆液性组织学与接受新辅助化疗相关;非临床因素如非裔美国人种族/族裔、低收入、高容量中心治疗及联邦医保也与接受新辅助化疗相关,其程度与临床相关因素相似。
要点
- 17302例晚期上皮性卵巢癌中,36.7%接受新辅助化疗,63.3%接受初始肿瘤细胞减灭术。
- 高龄、IV期、高级别和浆液性组织学与接受新辅助化疗独立相关。
- 非临床因素(种族/族裔、收入、中心容量、保险类型)与新辅助化疗使用相关,程度与临床因素相似。
核心结论
- 非临床因素与接受新辅助化疗相关,其程度与临床相关因素相似。
研究设计与样本
- 使用美国国家癌症数据库,纳入2012至2014年诊断为IIIC期和IV期上皮性卵巢癌的女性,共17302例符合条件。
- 主要结局为接受新辅助化疗,定义为化疗作为首个癌症导向治疗,不论是否行间隔手术;采用混合效应逻辑回归模型分析临床和非临床因素与新辅助化疗接受的单变量和多变量关联。
- 次要分析排除接受初始化疗但未行间隔肿瘤细胞减灭术的女性。
主要发现
- 17302例中,10948例(63.3%)接受初始肿瘤细胞减灭术,6354例(36.7%)接受新辅助化疗。
- 高龄、IV期疾病、高级别和浆液性组织学在接受新辅助化疗的单变量(p<0.001)和多变量分析(p<0.001)中均相关。
- 非临床因素单变量分析中,居住在东北地区和离家更近接受治疗与新辅助化疗相关(p<0.05),但多变量分析中不显著(p>0.05)。
- 多变量分析中,非裔美国人种族/族裔(p=0.04)、低收入水平(p=0.02)、在高容量中心治疗(p<0.01)以及由联邦医疗保险或其他政府保险覆盖(p<0.001)与接受新辅助化疗相关。
- 排除未接受手术的女性后,主要分析中所有独立预测新辅助化疗的因素除种族/族裔外仍显著。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify clinical and non-clinical factors associated with utilization of primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy (NACT) in women with advanced stage epithelial ovarian cancer (EOC). METHODS: Using the National Cancer Database, we identified women with stage IIIC and IV EOC diagnosed from 2012 to 2014. The primary outcome was receipt of NACT, defined in the primary analysis as utilization of chemotherapy as the first cancer-directed therapy, irrespective of whether interval surgery was performed. Univariable and multivariable associations between clinical and non-clinical factors and receipt of NACT were investigated using mixed-effect logistic regression models. A secondary analysis excluded women who received primary chemotherapy but did not receive interval cytoreductive surgery. RESULTS: Among 17,302 eligible women, 10,948 (63.3%) underwent PCS and 6354 (36.7%) received NACT. Older age, stage IV disease, high-grade, and serous histology were associated with receipt of NACT in univariate (p<0.001) and multivariable analyses (p<0.001). Analysis of non-clinical factors revealed that residency in the Northeast region and receipt of treatment closer to home were associated with NACT in univariate (p<0.05) but not multivariable analysis (p>0.05). In multivariable analysis, African-American race/ethnicity (p=0.04), low-income level (p=0.02), treatment in high-volume centers (p<0.01), and insurance by Medicare or other government insurance (p<0.001) were associated with receipt of NACT. When women who received no surgery were excluded, all factors that were independent predictors of NACT in the main analysis remained significant, except for race/ethnicity. CONCLUSIONS: Non-clinical factors were associated with the use of NACT at a magnitude similar to that of clinically relevant factors.
引用
- Hinchcliff E, Melamed A, Bregar A, et al. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. Gynecol Oncol. 2017. PMID: 29128105. doi:10.1016/j.ygyno.2017.10.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。